This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor.
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBC / P. Dreger, A. Sureda, K.W. Ahn, M. Eapen, C. Litovich, H. Finel, A. Boumendil, A. Gopal, A.F. Herrera, C. Schmid, J.L. Diez-Martin, E. Fuchs, J. Bolaños-Meade, M. Gooptu, M.M. Al Malki, L. Castagna, S.O. Ciurea, A. Dominietto, D. Blaise, F. Ciceri, J. Tischer, P. Corradini, S. Montoto, S. Robinson, Z. Gülbas, M. Hamadani. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:3(2019 Feb 12), pp. 360-369.
|Titolo:||PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBC|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||12-feb-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1182/bloodadvances.2018027748|
|Appare nelle tipologie:||01 - Articolo su periodico|